Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Development of a Selective Chemical Inhibitor for the Two-Pore Potassium Channel, KCNK9.

Miller MR, Zou B, Shi J, Flaherty DP, Simpson DS, Yao T, Maki BE, Day VW, Douglas JT, Wu M, McManus OB, Golden JE, Aubé J, Li M.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2012 Apr 16 [updated 2013 Feb 28].

2.

ML365: Development of Bis-Amides as Selective Inhibitors of the KCNK3/TASK1 Two Pore Potassium Channel.

Zou B, Flaherty DP, Simpson DS, Maki BE, Miller MR, Shi J, Wu M, McManus OB, Golden JE, Aubé J, Li M.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2013 Apr 15 [updated 2013 Nov 14].

3.

Identification of a novel, small molecule inhibitor of KCNQ2 channels.

Yu H, Xu K, Zou B, Wu M, McManus OB, Le Engers J, Cheung YY, Salovich JM, Hopkins CR, Lindsley CW, Li M.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2011 Oct 28 [updated 2013 Feb 25].

4.

Identification of a novel, small molecule activator of KCNQ1 channels.

Yu H, Lin Z, Xu K, Huang X, Long S, Wu M, McManus OB, Le Engers J, Mattmann ME, Engers DW, Le UM, Lindsley CW, Hopkins CR, Li M.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2011 Dec 16 [updated 2013 Mar 7].

5.

Terbinafine is a novel and selective activator of the two-pore domain potassium channel TASK3.

Wright PD, Veale EL, McCoull D, Tickle DC, Large JM, Ococks E, Gothard G, Kettleborough C, Mathie A, Jerman J.

Biochem Biophys Res Commun. 2017 Nov 4;493(1):444-450. doi: 10.1016/j.bbrc.2017.09.002. Epub 2017 Sep 5.

PMID:
28882594
6.

A pharmacologically validated, high-capacity, functional thallium flux assay for the human Ether-à-go-go related gene potassium channel.

Schmalhofer WA, Swensen AM, Thomas BS, Felix JP, Haedo RJ, Solly K, Kiss L, Kaczorowski GJ, Garcia ML.

Assay Drug Dev Technol. 2010 Dec;8(6):714-26. doi: 10.1089/adt.2010.0351.

PMID:
21158686
7.

K(+) efflux through two-pore domain K(+) channels is required for mouse embryonic development.

Hur CG, Kim EJ, Cho SK, Cho YW, Yoon SY, Tak HM, Kim CW, Choe C, Han J, Kang D.

Reproduction. 2012 May;143(5):625-36. doi: 10.1530/REP-11-0225. Epub 2012 Mar 14.

8.

The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG.

Rampe D, Murawsky MK, Grau J, Lewis EW.

J Pharmacol Exp Ther. 1998 Aug;286(2):788-93.

9.

The human ether-a'-go-go related gene (hERG) K+ channel blockade by the investigative selective-serotonin reuptake inhibitor CONA-437: limited dependence on S6 aromatic residues.

Alexandrou AJ, Milnes JT, Sun SZ, Fermini B, Kim SC, Jenkinson S, Leishman DJ, Witchel HJ, Hancox JC, Leaney JL.

J Physiol Pharmacol. 2014 Aug;65(4):511-23.

10.

Block of wild-type and inactivation-deficient human ether-a-go-go-related gene K+ channels by halofantrine.

Sánchez-Chapula JA, Navarro-Polanco RA, Sanguinetti MC.

Naunyn Schmiedebergs Arch Pharmacol. 2004 Dec;370(6):484-91. Epub 2004 Nov 19.

PMID:
15558243
11.

The 5-HT2 antagonist ketanserin is an open channel blocker of human cardiac ether-à-go-go-related gene (hERG) potassium channels.

Tang Q, Li ZQ, Li W, Guo J, Sun HY, Zhang XH, Lau CP, Tse HF, Zhang S, Li GR.

Br J Pharmacol. 2008 Oct;155(3):365-73. doi: 10.1038/bjp.2008.261. Epub 2008 Jun 23.

12.

Proton block of the pore underlies the inhibition of hERG cardiac K+ channels during acidosis.

Van Slyke AC, Cheng YM, Mafi P, Allard CR, Hull CM, Shi YP, Claydon TW.

Am J Physiol Cell Physiol. 2012 Jun 15;302(12):C1797-806. doi: 10.1152/ajpcell.00324.2011. Epub 2012 Apr 18.

13.

Extracellular sodium interacts with the HERG channel at an outer pore site.

Mullins FM, Stepanovic SZ, Desai RR, George AL Jr, Balser JR.

J Gen Physiol. 2002 Oct;120(4):517-37.

14.

Comparison of human Ether-à-go-go related gene screening assays based on IonWorks Quattro and thallium flux.

Bridal TR, Margulis M, Wang X, Donio M, Sorota S.

Assay Drug Dev Technol. 2010 Dec;8(6):755-65. doi: 10.1089/adt.2010.0267. Epub 2010 Jul 26.

PMID:
20658944
15.

Mechanism of block and identification of the verapamil binding domain to HERG potassium channels.

Zhang S, Zhou Z, Gong Q, Makielski JC, January CT.

Circ Res. 1999 May 14;84(9):989-98.

17.

Identification of quaternary ammonium compounds as potent inhibitors of hERG potassium channels.

Xia M, Shahane SA, Huang R, Titus SA, Shum E, Zhao Y, Southall N, Zheng W, Witt KL, Tice RR, Austin CP.

Toxicol Appl Pharmacol. 2011 May 1;252(3):250-8. doi: 10.1016/j.taap.2011.02.016. Epub 2011 Feb 26.

18.

Emerging issues of connexin channels: biophysics fills the gap.

Harris AL.

Q Rev Biophys. 2001 Aug;34(3):325-472. Review. Erratum in: Q Rev Biophys 2002 Feb;35(1):109.

PMID:
11838236
19.

KCNQ2/3 openers show differential selectivity and site of action across multiple KCNQ channels.

Zhang D, Thimmapaya R, Zhang XF, Anderson DJ, Baranowski JL, Scanio M, Perez-Medrano A, Peddi S, Wang Z, Patel JR, DeGoey DA, Gopalakrishnan M, Honore P, Yao BB, Surowy CS.

J Neurosci Methods. 2011 Aug 30;200(1):54-62. doi: 10.1016/j.jneumeth.2011.06.014. Epub 2011 Jun 23.

PMID:
21723881
20.

Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block.

Sánchez-Chapula JA, Navarro-Polanco RA, Culberson C, Chen J, Sanguinetti MC.

J Biol Chem. 2002 Jun 28;277(26):23587-95. Epub 2002 Apr 17.

Supplemental Content

Support Center